Latest News and Press Releases
Want to stay updated on the latest news?
-
DUBLIN, Ireland, May 10, 2013 (GLOBE NEWSWIRE) -- Further to media speculation, the Board of Warner Chilcott plc (Nasdaq:WCRX) confirmed today that the Company is engaged in preliminary discussions...
-
DUBLIN, Ireland, May 10, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced its results for the quarter ended March 31, 2013. Total revenue in the quarter ended March 31,...
-
DUBLIN, Ireland, May 9, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced that the United States Food and Drug Administration (FDA) has approved a new oral contraceptive,...
-
DUBLIN, Ireland, May 7, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced that its Board of Directors declared a semi-annual cash dividend in the amount of $0.25 per share,...
-
DUBLIN, Ireland, May 2, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced that its Board of Directors has voted unanimously to appoint Paul Herendeen, the Company's Executive...
-
DUBLIN, Ireland, May 1, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced that it will issue its first quarter 2013 financial results prior to the market opening on Friday,...
-
DUBLIN, Ireland, April 22, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced that the United States Food and Drug Administration (FDA) has approved MINASTRINTM 24 FE...
-
DUBLIN, Ireland, April 12, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced that the United States Food and Drug Administration (FDA) has approved a 200 mg strength of...
-
DUBLIN, Ireland, March 4, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced that its Executive Vice President and Chief Financial Officer, Paul Herendeen, is scheduled to...
-
DUBLIN, Ireland, Feb. 22, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced that its Executive Vice President and Chief Financial Officer, Paul Herendeen, is scheduled to...